What can be learned from the nda and bla reviews of newly approved drugs? A systematic review of drug interaction data for drugs approved by the US FDA IN 2014

被引：0
|
作者：
Yu, Jingjing [1 ]
Ritchie, Tasha K. [1 ]
Zhou, Zhu [1 ]
Ragueneau-Majlessi, Isabelle [1 ]
机构：
[1] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA
来源：
DRUG METABOLISM REVIEWS | 2016年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P112
引用
收藏
页码：81 / 81
页数：1
相关论文
共 20 条
  • [1] What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015
    Yu, Jingjing
    Zhou, Zhu
    Owens, Katie H.
    Ritchie, Tasha K.
    Ragueneau-Majlessi, Isabelle
    DRUG METABOLISM AND DISPOSITION, 2017, 45 (01) : 86 - 108
  • [2] RISK OF PHARMACOKINETIC DRUG-DRUG INTERACTIONS WITH NOVEL DRUGS APPROVED BY THE US FDA IN 2022: A DETAILED REVIEW OF DDI DATA FROM NDA DOCUMENTATION
    Yu, Jingjing
    Wang, Yan
    Ragueneau-Majlessi, Isabelle
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [3] Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
    Macklis, Paul C.
    Dulmage, Brittany
    Evans, Brady
    Rosenbach, Misha
    Gudjonsson, Johann E.
    Kaffenberger, Benjamin H.
    DRUGS IN R&D, 2020, 20 (03) : 171 - 187
  • [4] Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
    Paul C. Macklis
    Brittany Dulmage
    Brady Evans
    Misha Rosenbach
    Johann E. Gudjonsson
    Benjamin H. Kaffenberger
    Drugs in R&D, 2020, 20 : 171 - 187
  • [5] FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels
    Yao, Hui
    Rayburn, Elizabeth R.
    Shi, Qiang
    Gao, Liang
    Hu, Wenjie
    Li, Haibo
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2017, 54 (01) : 1 - 17
  • [6] Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016
    Saravanakumar, Anitha
    Sadighi, Armin
    Ryu, Rachel
    Akhlaghi, Fatemeh
    CLINICAL PHARMACOKINETICS, 2019, 58 (10) : 1281 - 1294
  • [7] Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016
    Anitha Saravanakumar
    Armin Sadighi
    Rachel Ryu
    Fatemeh Akhlaghi
    Clinical Pharmacokinetics, 2019, 58 : 1281 - 1294
  • [8] Oncology Dose Selection in Subsequent Indications: What Can We Learn From FDA-approved Oncology Drugs?
    Ngo, Huy X.
    Oh, Elise
    Li, Chunze
    Yu, Jiajie
    CLINICAL THERAPEUTICS, 2024, 46 (11) : 927 - 937
  • [9] UNDERSTANDING THE RISK OF CLINICALLY SIGNIFICANT PHARMACOKINETIC-BASED DRUG-DRUG INTERACTIONS WITH DRUGS NEWLY APPROVED BY THE US FDA - A REVIEW OF RECENT NEW DRUG APPLICATIONS (2013-2016)
    Yu, Jingjing
    Ragueneau-Majlessi, Isabelle
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S46 - S47
  • [10] Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability
    Modi, Natansh D.
    Swain, Sandra M.
    Buyse, Marc
    Kuderer, Nicole M.
    Rowland, Andrew
    Rockhold, Frank W.
    Sorich, Michael J.
    Hopkins, Ashley M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (32)
12